WallStreetZenWallStreetZen

NASDAQ: AVBP
Arrivent Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AVBP

Based on 6 analysts offering 12 month price targets for Arrivent Biopharma Inc

Min Forecast
$42.00+24.17%
Avg Forecast
$44.83+32.54%
Max Forecast
$50.00+47.82%

Should I buy or sell AVBP stock?

Based on 6 analysts offering ratings for Arrivent Biopharma Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AVBP's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AVBP as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their AVBP stock forecasts and price targets.

AVBP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-29
lockedlocked$00.00+00.00%2026-05-13
lockedlocked$00.00+00.00%2026-03-23
lockedlocked$00.00+00.00%2026-03-12
lockedlocked$00.00+00.00%2026-03-06
HC Wainwright & Co.
Top 5%
96
BuyMaintains$44.00+30.08%2026-03-06

1 of 1

Forecast return on equity

Is AVBP forecast to generate an efficient return?

Company
18%
Industry
92.07%
Market
175.23%
AVBP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AVBP forecast to generate an efficient return on assets?

Company
16.7%
Industry
27.49%
AVBP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AVBP earnings per share forecast

What is AVBP's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
-$4.15
Avg 2 year Forecast
-$3.60
Avg 3 year Forecast
-$1.36

AVBP revenue forecast

What is AVBP's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$48.1M
Avg 3 year Forecast
$192.4M

AVBP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVBP$33.83$44.83+32.54%Strong Buy
GHRS$25.34$41.67+64.43%Strong Buy
MRVI$6.12$5.50-10.13%Strong Buy
AAPG$17.05$46.50+172.73%Strong Buy
ABSI$10.21$13.00+27.33%Strong Buy
View Top Biotech Stocks

Arrivent Biopharma Stock Forecast FAQ

Is Arrivent Biopharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: AVBP) stock is to Strong Buy AVBP stock.

Out of 6 analysts, 4 (66.67%) are recommending AVBP as a Strong Buy, 2 (33.33%) are recommending AVBP as a Buy, 0 (0%) are recommending AVBP as a Hold, 0 (0%) are recommending AVBP as a Sell, and 0 (0%) are recommending AVBP as a Strong Sell.

If you're new to stock investing, here's how to buy Arrivent Biopharma stock.

What is AVBP's earnings growth forecast for 2026-2028?

(NASDAQ: AVBP) Arrivent Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.64%.

Arrivent Biopharma's earnings in 2026 is -$145,241,000.On average, 15 Wall Street analysts forecast AVBP's earnings for 2026 to be -$193,174,171, with the lowest AVBP earnings forecast at -$210,872,644, and the highest AVBP earnings forecast at -$162,360,199. On average, 13 Wall Street analysts forecast AVBP's earnings for 2027 to be -$167,809,466, with the lowest AVBP earnings forecast at -$237,802,267, and the highest AVBP earnings forecast at -$107,294,662.

In 2028, AVBP is forecast to generate -$63,230,122 in earnings, with the lowest earnings forecast at -$129,170,905 and the highest earnings forecast at $62,596,703.

What is AVBP's revenue growth forecast for 2026-2028?

(NASDAQ: AVBP) Arrivent Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.42%.

Arrivent Biopharma's revenue in 2026 is $0.On average, 12 Wall Street analysts forecast AVBP's revenue for 2026 to be $0, with the lowest AVBP revenue forecast at $0, and the highest AVBP revenue forecast at $0. On average, 13 Wall Street analysts forecast AVBP's revenue for 2027 to be $2,239,322,538, with the lowest AVBP revenue forecast at $68,465,144, and the highest AVBP revenue forecast at $3,929,899,275.

In 2028, AVBP is forecast to generate $8,961,947,646 in revenue, with the lowest revenue forecast at $4,400,026,598 and the highest revenue forecast at $12,822,543,428.

What is AVBP's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: AVBP) forecast ROA is 16.7%, which is lower than the forecast US Biotechnology industry average of 27.49%.

What is AVBP's Price Target?

According to 6 Wall Street analysts that have issued a 1 year AVBP price target, the average AVBP price target is $44.83, with the highest AVBP stock price forecast at $50.00 and the lowest AVBP stock price forecast at $42.00.

On average, Wall Street analysts predict that Arrivent Biopharma's share price could reach $44.83 by May 29, 2027. The average Arrivent Biopharma stock price prediction forecasts a potential upside of 32.54% from the current AVBP share price of $33.83.

What is AVBP's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AVBP) Arrivent Biopharma's current Earnings Per Share (EPS) is -$3.47. On average, analysts forecast that AVBP's EPS will be -$4.15 for 2026, with the lowest EPS forecast at -$4.53, and the highest EPS forecast at -$3.49. On average, analysts forecast that AVBP's EPS will be -$3.60 for 2027, with the lowest EPS forecast at -$5.11, and the highest EPS forecast at -$2.30. In 2028, AVBP's EPS is forecast to hit -$1.36 (min: -$2.77, max: $1.34).

What is AVBP's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: AVBP) forecast ROE is 18%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.